Invesaro

Stocks Comparison

Exelixis vs Gilead Sciences: revenue, profit, margins and growth compared

Exelixis brought in $2.3B of revenue in fiscal 2025, Gilead Sciences $29.4B in fiscal 2025. Revenue changed by +7.0% at Exelixis and +2.4% at Gilead Sciences on the year before, so Exelixis grew faster. Exelixis kept 33.7% of its revenue as net profit, Gilead Sciences 28.9%. Free cash flow was $875.8M at Exelixis and $9.5B at Gilead Sciences.

Side by side, latest fiscal year

EXELGILD
Fiscal year endedFY2025 (January 2, 2026)FY2025 (December 31, 2025)
Revenue$2.3B$29.4B
Revenue growth+7.0%+2.4%
Net income$782.6M$8.5B
Net margin33.7%28.9%
Free cash flow$875.8M$9.5B
Free cash flow margin37.7%32.1%
Earnings per share (diluted)$2.78$6.78
Cash$482.5M$7.6B
Debtn/a$24.9B
Price to earnings20.922.3
Market value$14.4B$187.1B
Dividend yieldn/a2.09%
Rank by revenue in sector#100 of 523 · Health care#22 of 523 · Health care

Over the years

Revenue
EXEL FY2018: $853.8MEXEL FY2019: $967.8MEXEL FY2020: $987.5MEXEL FY2021: $1.4BEXEL FY2022: $1.6BEXEL FY2023: $1.8BEXEL FY2024: $2.2BEXEL FY2025: $2.3BGILD FY2018: $22.1BGILD FY2019: $22.4BGILD FY2020: $24.7BGILD FY2021: $27.3BGILD FY2022: $27.3BGILD FY2023: $27.1BGILD FY2024: $28.8BGILD FY2025: $29.4BFY18FY19FY20FY21FY22FY23FY24FY25
EXEL $2.3BGILD $29.4B
Net income
EXEL FY2018: $690.1MEXEL FY2019: $321MEXEL FY2020: $111.8MEXEL FY2021: $231.1MEXEL FY2022: $182.3MEXEL FY2023: $207.8MEXEL FY2024: $521.3MEXEL FY2025: $782.6MGILD FY2018: $5.5BGILD FY2019: $5.4BGILD FY2020: $123MGILD FY2021: $6.2BGILD FY2022: $4.6BGILD FY2023: $5.7BGILD FY2024: $480MGILD FY2025: $8.5BFY18FY19FY20FY21FY22FY23FY24FY25
EXEL $782.6MGILD $8.5B
Net margin
EXEL FY2018: 80.8%EXEL FY2019: 33.2%EXEL FY2020: 11.3%EXEL FY2021: 16.1%EXEL FY2022: 11.3%EXEL FY2023: 11.4%EXEL FY2024: 24.0%EXEL FY2025: 33.7%GILD FY2018: 24.7%GILD FY2019: 24.0%GILD FY2020: 0.5%GILD FY2021: 22.8%GILD FY2022: 16.8%GILD FY2023: 20.9%GILD FY2024: 1.7%GILD FY2025: 28.9%FY18FY19FY20FY21FY22FY23FY24FY25
EXEL 33.7%GILD 28.9%
Revenue growth
EXEL FY2019: +13.3%EXEL FY2020: +2.0%EXEL FY2021: +45.3%EXEL FY2022: +12.3%EXEL FY2023: +13.6%EXEL FY2024: +18.5%EXEL FY2025: +7.0%GILD FY2019: +1.5%GILD FY2020: +10.0%GILD FY2021: +10.6%GILD FY2022: -0.1%GILD FY2023: -0.6%GILD FY2024: +6.0%GILD FY2025: +2.4%FY19FY20FY21FY22FY23FY24FY25
EXEL +7.0%GILD +2.4%
Free cash flow
EXEL FY2018: $382.4MEXEL FY2019: $514.1MEXEL FY2020: $178.6MEXEL FY2021: $346.6MEXEL FY2022: $334.9MEXEL FY2023: $292.9MEXEL FY2024: $671.5MEXEL FY2025: $875.8MGILD FY2018: $7.5BGILD FY2019: $8.3BGILD FY2020: $7.5BGILD FY2021: $10.8BGILD FY2022: $8.3BGILD FY2023: $7.4BGILD FY2024: $10.3BGILD FY2025: $9.5BFY18FY19FY20FY21FY22FY23FY24FY25
EXEL $875.8MGILD $9.5B

Fiscal years as each company reports them; the two may end in different months.

Questions about Exelixis and Gilead Sciences

Which is bigger by revenue, Exelixis or Gilead Sciences?

Gilead Sciences is bigger by revenue: $29.4B in fiscal 2025, against $2.3B for Exelixis in fiscal 2025.

Which keeps more of its revenue as profit, Exelixis or Gilead Sciences?

Exelixis had a net margin of 33.7% in fiscal 2025; Gilead Sciences had 28.9% in fiscal 2025.

Which grew revenue faster, Exelixis or Gilead Sciences?

In their latest fiscal years revenue changed by +7.0% at Exelixis and +2.4% at Gilead Sciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies